Synriam is India’s first
indigenously developed anti-malarial drug. It beats all currently
available options on the counts of affordability, compliance and relief.
The drug is the result of first successful public-private partnership
on pharmaceutical research and development in India. Ranbaxy and the
Ministry of Science paid Rs 5 crore each for the development of the
drug.
No comments:
Post a Comment